NEXUS ON GRAND LEASELease • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • California
This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and MYRIAD GENETICS, INC., a Delaware corporation ("Tenant").
LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase I)Lease Termination Agreement • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances
THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the “Parties”), with reference to the following recitals:
SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMSSeparation and Consulting Agreement and Release of Claims • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of December 15, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and R. Bryan Riggsbee (“Executive” and together with the Company, the “Parties” and each a “Party”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
This Executive Employment Agreement (the “Agreement”), made and entered into this 15th day of December, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Scott Leffler (“Executive”).
LEASE 322 North 2200 West (Building D) Salt Lake City, Utah LESSOR: BAY BRIDGE/CORPORATE, LLC LESSEE: MYRIAD GENETICS, INC.Disturbance and Attornment Agreement • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
This Lease dated as of the later date set forth next to the parties’ signatures below (the “Lease Date”), is made by and between Bay Bridge/Corporate, LLC, a Delaware limited liability company (“Lessor”), and Myriad Genetics, Inc., a Delaware corporation (“Lessee”).
SEVERANCE AND CHANGE OF CONTROL AGREEMENTSeverance and Change of Control Agreement • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on December 11, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Employee”).
